BRAVOO study Better understanding of reactive arthritis in children to prevent overtreatment and unnecessary consumption of care

BRAVOO study Better understanding of reactive arthritis in children to prevent overtreatment and unnecessary consumption of care - BRAVOO study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54224

Enrollment

200

Registered

2020-10-02

Start date

2021-03-15

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis inflammation of the joint

Interventions

None listed

Eligibility

Age

No minimum to 17 Years

Inclusion criteria

Inclusion criteria: -First presentation of arthritis with a maximum duration of six weeks -Children from six months - 18 years of age

Exclusion criteria

Exclusion criteria: -Patients already known with juvenile idiopathic arthritis or any diagnosis that is related with arthritis (for example IgA vasculitis) -Patients known with immunodeficiency disorders -Insufficient understanding of Dutch language

Design outcomes

Primary

Measure	Time frame
This is an observational cohort study, in which we aim to answer five research questions during emergency department/outpatient clinic visits for routine clinical care. The study will lead to the following main study endpoints: 1. Determine the role of currently known pathogens in children with arthritis. 2. Determine whether anti-streptolysine O and DNAse-B testing is a reliable method to diagnose post-streptococcal reactive arthritis. 3. Investigate the link between Mycoplasma pneumoniae and childhood arthritis using a new diagnostic method. 4. Using "viral meta-genomics" to investigate whether unknown viruses can be associated with reactive arthritis in children. 5. Developing an evidence-based (inter) national guideline for the diagnosis of arthritis in children.	—

Measure

Time frame

This is an observational cohort study, in which we aim to answer five research questions during emergency department/outpatient clinic visits for routine clinical care. The study will lead to the following main study endpoints: 1. Determine the role of currently known pathogens in children with arthritis. 2. Determine whether anti-streptolysine O and DNAse-B testing is a reliable method to diagnose post-streptococcal reactive arthritis. 3. Investigate the link between Mycoplasma pneumoniae and childhood arthritis using a new diagnostic method. 4. Using "viral meta-genomics" to investigate whether unknown viruses can be associated with reactive arthritis in children. 5. Developing an evidence-based (inter) national guideline for the diagnosis of arthritis in children.

—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results